ArticleCureus2025
Correlation of Fibrinogen-Albumin Ratio With Gensini Score in ST-Segment Elevation Myocardial Infarction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction ST-segment elevation myocardial infarction (STEMI) is a severe form of coronary artery disease (CAD) often associated with systemic inflammation. The fibrinogen-albumin ratio (FAR) has been proposed as a novel inflammatory marker with potential prognostic value. The Gensini score, derived from coronary angiography, quantifies the severity of CAD. This study aimed to assess the correlation between FAR and Gensini score in STEMI patients. Materials and methods A cross-sectional observational study was conducted at a tertiary care center in Karnataka, India, from May 2023 to December 2024. Seventy patients with a clinical diagnosis of STEMI were enrolled. Clinical evaluation, blood tests (including fibrinogen and albumin levels), echocardiography, and coronary angiography were performed. FAR was calculated by dividing fibrinogen (g/L) by albumin (g/L), and Gensini scores were computed to assess CAD severity. Statistical analysis included Pearson's correlation and the chi-squared test. Results The study population comprised mostly men (47, 67.14%) and individuals aged over 60 years (40, 57.14%). Single and double vessel disease were each present in 24 (34.3%) patients. FAR >0.1 was seen in 37 (52.86%). A significant association was found between Gensini score and the extent of vessel disease (p=0.0001); however, FAR did not show a statistically significant correlation with Gensini score (r=-0.002; p=0.989). FAR also lacked a significant association with heart failure types. Conclusion FAR may have limited utility in predicting angiographic severity in patients with STEMI. While it remains a simple and economical inflammatory marker, its prognostic relevance in acute coronary events appears uncertain. Further research with larger cohorts is warranted to validate its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.